{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:38:14Z","timestamp":1793968694367,"version":"4.8.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,5,26]]},"DOI":"10.1038\/s41416-020-0787-9","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T23:07:02Z","timestamp":1585868822000},"page":"1577-1579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Triage of HPV-positive women in Norway using cytology, HPV16\/18 genotyping and HPV persistence"],"prefix":"10.1038","volume":"122","author":[{"given":"Marc","family":"Arbyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remila","family":"Rezhake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Yuill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Canfell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"issue":"Suppl 5","key":"787_CR1","doi-asserted-by":"publisher","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","volume":"30","author":"M Arbyn","year":"2012","unstructured":"Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J. L. M., Poljak, M., Ogilvie, G. et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30(Suppl 5), F88\u2013F99 (2012).","journal-title":"Vaccine"},{"key":"787_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco, G., Dillner, J., Elfstrom, K. M., Tunesi, S., Snijders, P. J., Arbyn, M. et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383, 524\u2013532 (2014).","journal-title":"Lancet"},{"key":"787_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pvr.2015.06.006","volume":"1","author":"L von Karsa","year":"2015","unstructured":"von Karsa, L., Arbyn, M., De Vuyst, H., Dillner, J., Dillner, L., Franceschi, S. et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavir. Res. 1, 22\u201331 (2015).","journal-title":"Papillomavir. Res."},{"key":"787_CR4","doi-asserted-by":"publisher","unstructured":"Hashim, D., Engesaeter, B., Baadstrand Skare, G., Castle, P. E., Bjorge, T., Trope, A. et al. Real world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. Br. J. Cancer (2020). https:\/\/doi.org\/10.1038\/s41416-020-0790-1.","DOI":"10.1038\/s41416-020-0790-1"},{"key":"787_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.7326\/M15-2735","volume":"166","author":"M Arbyn","year":"2017","unstructured":"Arbyn, M., Xu, L., Verdoodt, F., Cuzick, J., Szarewski, A., Belinson, J. et al. Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis. Ann. Intern. Med. 166, 118\u2013127 (2017).","journal-title":"Ann. Intern. Med."},{"key":"787_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/bjc.2011.351","volume":"105","author":"M Arbyn","year":"2011","unstructured":"Arbyn, M., Roelens, J., Martin-Hirsch, P., Leeson, S. & Wentzensen, N. Use of HC2 to triage women with borderline and mild dyskaryosis in the UK. Br. J. Cancer 105, 877\u2013880 (2011).","journal-title":"Br. J. Cancer"},{"key":"787_CR7","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S1470-2045(17)30700-3","volume":"18","author":"M Arbyn","year":"2017","unstructured":"Arbyn, M., Redman, C. W. E., Verdoodt, F., Kyrgiou, M., Tzafetas, M., Ghaem-Maghami, S. et al. Incomplete excision of cervical pre-cancer as predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol. 18, 1665\u20131679 (2017).","journal-title":"Lancet Oncol."},{"key":"787_CR8","unstructured":"Arbyn, M., Lion, L., Yuill, S., Gultekin, M. & Canfell, K. ESGO meta-analysis: triage of HPV-positive women. 21st European Congress on Gynaecological Oncology (21st European Congress on Gynaecological Oncology, Athens, 2019)."},{"key":"787_CR9","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1097\/LGT.0b013e318285423c","volume":"17","author":"HA Katki","year":"2013","unstructured":"Katki, H. A., Schiffman, M., Castle, P. E., Fetterman, B., Poitras, N. E., Lorey, T. et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J. Low. Genit. Trac. Dis. 17, S28\u2013S35 (2013).","journal-title":"J. Low. Genit. Trac. Dis."},{"key":"787_CR10","doi-asserted-by":"crossref","unstructured":"Machalek, D. A., Roberts, J. M., Garland, S. M., Thurloe, J., Richards, A., Chambers, I. et al. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program. Med. J. Aust. 211, 113\u2013119 (2019).","DOI":"10.5694\/mja2.50223"},{"key":"787_CR11","doi-asserted-by":"publisher","first-page":"e1002388","DOI":"10.1371\/journal.pmed.1002388","volume":"14","author":"K Canfell","year":"2017","unstructured":"Canfell, K., Caruana, M., Gebski, V., Darlington-Brown, J., Heley, S., Brotherton, J. et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the compass pilot randomised trial. PLoS Med. 14, e1002388 (2017).","journal-title":"PLoS Med."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0787-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0787-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0787-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T18:10:03Z","timestamp":1655316603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0787-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,5,26]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0787-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"K.C. is co-principal investigator of an unrelated investigator-initiated trial of cervical screening in Australia (Compass, ACTRN12613001207707 and NCT02328872), which is conducted and funded by the VCS Foundation (VCS), a government-funded health promotion charity. The VCS Foundation received equipment and a funding contribution from Roche Molecular Systems USA. However, neither K.C. nor her institution on her behalf (Cancer Council NSW) receives direct funding from industry for this trial or any other project. MA was supported by the European Society of Gynaecological Oncology; the Cancer Council of New South Wales, Sydney (Australia); the RISCC Network, funded by the Horizon 2020 programme, of DG Research and Innovation, European Commission and the High Authority for Health (Paris, France).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"ESGO, Cancer Council NSW (Australia) and European Commission, HAS (France).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}